Skip to Content
Merck
All Photos(1)

Documents

Safety Information

V3640

Sigma-Aldrich

Valpromide

≥97% (NMR)

Synonym(s):

2-Propylvaleramide, 2-propyl-pentanamide, Depamid, Depamide, Di-n-propylacetamide, Dipropylacetamide

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C8H17NO
CAS Number:
2430-27-5
Molecular Weight:
143.23
MDL number:
MFCD00051534
UNSPSC Code:
12352200
PubChem Substance ID:
329829044
NACRES:
NA.77

Assay

≥97% (NMR)

form

powder

color

white to off-white

solubility

DMSO: >10 mg/mL

originator

Sanofi Aventis

storage temp.

room temp

SMILES string

CCCC(CCC)C(N)=O

InChI

1S/C8H17NO/c1-3-5-7(6-4-2)8(9)10/h7H,3-6H2,1-2H3,(H2,9,10)

InChI key

OMOMUFTZPTXCHP-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

Application

Valpromide has been used to pretreat NIH/3T3 cells to test its effect on cytomegalovirus (CMV) viral replication. It has also been used to test its antiviral functionality in herpes simplex virus type 1 (HSV-1) infected human oligodendroglioma (HOG) cells. It may be used to test its effect on apoptosis induction in astrocytes.

Biochem/physiol Actions

Valpromide (VPD) is a derivative of valproic acid (VPA) and is used as an antiepileptic drug. It is hydrolyzed quickly to VPA in vivo, but has intrinsic anticonvulsant activity.
Valpromide possesses antipsychotic property. It lacks the toxic and teratogenic effects of valproic acid. It also lacks the histone deacetylase (HDAC) inhibitory activity of valproic acid.

Features and Benefits

This compound was developed by Sanofi Aventis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Pictograms

Exclamation mark
GHS07

Signal Word

Warning

Hazard Statements

H302

Precautionary Statements

P264 - P270 - P301 + P312 - P501

Hazard Classifications

Acute Tox. 4 Oral

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Regulatory Listings

Regulatory Listings are mainly provided for chemical products. Only limited information can be provided here for non-chemical products. No entry means none of the components are listed. It is the user’s obligation to ensure the safe and legal use of the product.

JAN Code

V3640-VAR:
V3640-10MG:
V3640-BULK:
V3640-50MG:

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Galit Shaltiel et al.
Biological psychiatry, 56(11), 868-874 (2004-12-04)
Lithium and valproate (VPA) are used for treating bipolar disorder. The mechanism of mood stabilization has not been elucidated, but the role of inositol has gained substantial support. Lithium inhibition of inositol monophosphatase, an enzyme required for inositol recycling and
Joseph R Calabrese et al.
Bipolar disorders, 9(6), 628-635 (2007-09-12)
Agomelatine has been shown to be safe and efficient in the treatment of major depressive disorder at 25 mg daily. The aim of this study was to gather preliminary data regarding the antidepressant efficacy of agomelatine in patients with bipolar
M Bialer
Clinical pharmacokinetics, 20(2), 114-122 (1991-02-01)
Valpromide has been used as an antiepileptic and antipsychotic drug for the past 25 years in several European countries. Unlike its corresponding acid, valproic acid, whose pharmacokinetics have been quite extensively reviewed, and despite years of clinical use, it appears
Valproic acid induces apoptosis in differentiating hippocampal neurons by the release of tumor necrosis factor-alpha from activated astrocytes
Wang C, et al.
Neuroscience Letters, 497(2), 122-127 (2011)
Karine Cambon et al.
Molecular therapy. Methods & clinical development, 5, 259-276 (2017-06-13)
Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder resulting from a polyglutamine expansion in the huntingtin (HTT) protein. There is currently no cure for this disease, but recent studies suggest that RNAi to downregulate the expression of both normal
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service